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ABSTRACT
background: Increased blood pressure variability is a novel risk factor for the development of target organ injury both in hyperten-
sive and normotensive subjects, so its reduction should be considered as a new therapeutic goal.
Objective: The aim of this study was to evaluate the effect of long-term oral carvedilol treatment on blood pressure, blood pressure 
variability and target organ injury in the left ventricle and thoracic aorta in a model of blood pressure liability.
Methods: Twelve male Wistar rats submitted to sinoaortic denervation were treated during 8 weeks with a single dose of carvedilol 
30 mg/kg or vehicle. At the end of treatment, echocardiographic evaluation and blood pressure and short-term variability measure-
ments were performed. Left ventricular and thoracic aortic weights were determined and histological samples were prepared from 
both tissues. Metalloproteinase MMP-2 and transforming growth factor β (TGF-β) were quantified in the left ventricle and thoracic 
aorta.
results: Carvedilol reduced systolic blood pressure and its variability in sinoaortic-denervated rats compared with the control group 
(126±5 vs. 142±11 mmHg, p<0.05; SD: 2.9±0.5 vs. 6.0±0.5 mmHg; p<0.05). A lower amount of connective tissue was found in 
carvedilol-treated animals. The expression of TGF-β decreased in both organs after carvedilol treatment.
Conclusions: Chronic carvedilol treatment significantly reduces systolic blood pressure and its short-term variability in sinoaortic-
denervated rats, decreasing the degree of left ventricular fibrosis.
Key words: Carvedilol - Target Organ Injury - Sinoaortic Denervation - Blood Pressure Variability - Ventricular Hypertrophy
RESUMEN
introducción: El incremento en la variabilidad de la presión arterial resulta un nuevo factor de riesgo para el desarrollo de daño 
de órgano blanco en individuos tanto hipertensos como normotensos, por lo que se postula que su reducción debe considerarse una 
posible nueva meta terapéutica.
Objetivos: Evaluar el efecto del tratamiento a largo plazo con carvedilol sobre la presión arterial, su variabilidad y el daño de órgano 
blanco en el ventrículo izquierdo y la aorta torácica en el modelo de la labilidad de presión.
Material y métodos: Se incluyeron 12 ratas Wistar macho sometidas a desnervación sinoaórtica, las cuales fueron tratadas durante 
8 semanas con una única administración diaria de carvedilol 30 mg/kg o vehículo. Finalizado el tratamiento se realizó la medición 
de la presión arterial y de la variabilidad a corto plazo y la evaluación ecocardiográfica. Se determinó el peso del ventrículo y de la 
aorta torácica y se realizaron preparados histológicos sobre ambos tejidos. Se cuantificó la expresión de metaloproteinasa 2 (MMP-2) 
y factor de crecimiento transformante β (TGF-β) en el ventrículo izquierdo y la aorta torácica.
resultados: El carvedilol redujo la presión arterial sistólica y su variabilidad en las ratas con desnervación sinoaórtica en compar-
ación con el grupo control (126 ± 5 vs. 142 ± 11 mm Hg, p < 0,05; DE: 2,9 ± 0,5 vs. 6,0 ± 0,5 mm Hg; p < 0,05). Se evidenció menor 
cantidad de tejido conectivo en los animales tratados con carvedilol. La expresión de TGF-β se encuentra disminuida en ambos órga-
nos luego del tratamiento con carvedilol.
Conclusiones: El tratamiento crónico con carvedilol reduce significativamente la presión arterial y su variabilidad a corto plazo en 
ratas con desnervación sinoaórtica, disminuyendo el grado de fibrosis del ventrículo izquierdo.
Palabras clave: Carvedilol - Daño de órgano blanco - Desnervación sinoaórtica - Variabilidad de la presión arterial - Hipertrofia 
ventricular
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INTRODUCTION
Blood pressure (BP) is not a constant variable, as it 
presents short-term (from minutes to days) and long-
term (months) periods of deep and spontaneous oscil-
lations. (1) The increase in blood pressure variability 
(BPV) has been established as a risk factor for the 
development of target organ injury not only in hyper-
tensive patients but also in normotensive subjects. 
(1, 2) Clinical studies have determined that 24-hour, 
day-to-day and between medical visits increased BP 
fluctuations are associated with higher risk of major 
cardiovascular events in the hypertensive population. 
(3) Taking into account this association, it is now pos-
tulated that the reduction in BPV should be regarded 
as a new therapeutic goal of antihypertensive therapy. 
(3)
Beta-blockers, which until recently had been con-
sidered as first line therapy in hypertensive patients 
without concomitant diseases, are no longer recom-
mended for the initial treatment in uncomplicated 
hypertensive patients due to their lower protection 
of cerebrovascular events and higher risk of meta-
bolic disorders. (4) One of the possible reasons asso-
ciated to beta-blocker reduced target organ protec-
tion is the lower attenuation of BPV compared with 
other antihypertensive agents, especially calcium 
blockers. (5) However, the clinical evidence associat-
ing use of beta-blockers with reduced cardiovascular 
protection of the hypertensive patient is based to a 
great extent on clinical studies evaluation atenolol, 
a beta-blocker with relatively low cardioselectivity 
and no vasodilator effect. (3, 4) In the last decades, 
third-generation vasodilating beta-blockers have 
been developed, among them carvedilol and nebivolol, 
with better pharmacological properties than atenolol, 
including the ability to reduce central BP and with 
neutral metabolic profile. (4) However, the superiority 
of third-generation vasodilating beta-blockers over at-
enolol for the reduction of BPV has not been assessed 
in clinical studies. In a previous work performed in 
rats submitted to sinoaortic denervation, a model of 
BP liability, we showed that acute administration of 
carvedilol and nebivolol reduces short-term BPV to a 
greater extent than atenolol. (6)
Thus, the purpose of this study was to analyze the 
effects of chronic carvedilol administration on BP and 
its variability in SAD rats and its possible impact on 
target organ injury at the left ventricular and aortic 
levels.
METHODS
Male Wistar rats (200-220 g) were used. They were submit-
ted to sinoaortic denervation using the Krieger method con-
sisting in sectioning the aortic nerves at the carotid artery 
level and the bilateral dissection of carotid bifurcations to 
remove the carotid nerves. (6) Animals were treated during 
8 weeks with carvedilol 30 mg/kg (n=6) or vehicle (n=6), 
administered orally through a trocar. During the last two 
weeks of treatment systolic blood pressure (SBP) was meas-
ured by the indirect tail-cuff method at 1:00 PM. Mean SBP, 
intraday variations and interday fluctuations were estimat-
ed from these measurements. 
In the last week of treatment, echocardiographic meas-
urements were performed in anesthetized rats with a combi-
nation of ketamine/xylazine using an Acuson Sequoia C512 
ultrasound system, equipped with a 7-14 MHz transducer. At 
the end of the two-month treatment, the carotid artery was 
cannulated and connected, 24 hours later, to a Spectramed 
P23XL pressure transducer (Spectramed, Oxnard, CA, 
USA) coupled to a Grass 79D polygraph (Grass Instruments, 
Quincy, MA, USA). The polygraph was connected to a digital 
converter (Poliview, PVA 1, Grass-Astro Med, West Warwick, 
RI, USA), and 2-hour BP recordings were stored and ana-
lyzed with Poliview 2.3 software (Astro Med, West Warwick, 
RI, USA). Mean arterial pressure (MAP), heart rate, and 
short-term BPV from 3-minute recordings were calculated. 
In addition, beat-to-beat variability was evaluated from the 
spectral analysis of BP using Fast Fourier Transform with a 
Hamming window. Spectral densities were calculated in the 
very low frequency (VLF) (0.1-0.2 Hz), low frequency (LF) 
(0.2-0.7 Hz) and high frequency (HF) (0.7-2.5 Hz) ranges. 
Although it is well-known that LF variability is subject to 
modulation of neural sympathetic vascular tone, the LF/HF 
ratio was used as an index of this activity, as this normaliza-
tion procedure tends to reduce the effect of changes in the 
absolute values of BPV at LF. (7, 8)
After hemodynamic parameters were measured, all ani-
mals were sacrificed by decapitation, and the thoracic aorta 
and left ventricle were removed to assess target organ in-
jury. The left ventricular weight/body weight ratio and the 
aortic weight/length ratio were assessed using a precision 
balance as morphological markers of target organ injury. (9) 
Presence of fibrosis was determined by left ventricular histo-
pathological evaluation on 4-mm thick histological sections 
according to previous studies in rats with sinoaortic dener-
vation, (9) using Sirius Red to stain collagen fibers pink.
Finally, metalloproteinase MMP-2 (MMP-2) and trans-
forming growth factor β (TGF-β) expressions were assessed 
by Western blot as biochemical injury markers in left ven-
tricular and thoracic aorta homogenates. The homogenates 
(20 μ) were run in polyacrylamide gel SDS (12%). Transfer 
was performed on PVDF membranes and after blocking were 
incubated overnight with Rabbit anti-MMP-2 (PM 63 kDa), 
Mouse anti-TGF-β1 (PM 13 kDa) and Rabbit anti-GAPDH 
(PM 37 kDa) as loading control. Proteins were detected by 
abbreviations 
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bPV  Blood pressure variability
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ventricle as in the thoracic aorta compared with the 
control group treated with vehicle (Figures 3 and 4). 
Conversely, no significant differences were detected in 
MMP-2 expression in both tissues between carvedilol 
and control groups
DISCUSSION
The present study shows that chronic oral treatment 
with the third-generation vasodilating beta-blocker 
carvedilol significantly reduces short-term BPV in 
SAD rats. However, in the carvedilol group, this in-
dependent cardiovascular risk marker is only associ-
ated with reduction of myocardial fibrosis without 
changes in morphological measurements and echo-
chemiluminescence using photographic film and were quan-
tified with the ImageJ program. (10)
 
statistical analysis
The Kolmogorov Smirnov test was used to verify normal 
distribution of data and variables. Data were expressed as 
mean±standard error of the mean. Statistical comparisons 
between both groups were performed with Student´s t test 
using GraphPad Prism version 5.02 for Windows (GraphPad 
Software, San Diego, California, USA). Statistical signifi-
cance was defined as p<0.05.
Ethical considerations
Animal experiments were performed according to the “Guide 
for the Care and Use of Laboratory Animals” (NIH Publica-
tion No. 85–3, revised 1985).
RESULTS 
The analysis of tail-cuff BP measurements showed 
that chronic carvedilol treatment reduced SBP and 
its intraday variation without modifying SBP fluctua-
tions between interday measurements (Table 1). Cen-
tral BP measured in the carotid artery of cannulated 
SAD animals did not show significant differences in 
MAP between rats treated with carvedilol 30 mg/kg 
and those that received vehicle (Table 1). However, 
chronic carvedilol treatment reduced short-term BPV 
evidenced by a significant reduction of standard de-
viation compared with the control group (Table 1). 
Spectral analysis evaluation of BP recordings estab-
lished that chronic treatment with carvedilol pro-
duces a highly significant reduction of beat-to beat 
BPV in all the frequency domains compared with the 
control group (Figure 1). Moreover, the LF/HF index, 
a marker of sympathetic vascular tone, was lower in 
SAD rats receiving carvedilol 30 mg/kg compared with 
animals treated with vehicle.
Target organ injury in the left ventricle and tho-
racic aorta was different in SAD animals treated with 
carvedilol or vehicle. The left ventricular weight/body 
weight ratio was similar in the group of SAD rats re-
ceiving vehicle (2.29±0.04, n=6) and those treated 
with carvedilol 30 mg/kg (2.47±0.12, n=6). Also, no 
significant differences were detected in the thoracic 
aorta weight/length ratio between animals treated 
with carvedilol (2.55±0.35 mg/mm, n=6) and the con-
trol group (3.07±0.21 mg/mm, n=6).
Echocardiographic evaluation did not reveal sig-
nificant differences in the main echocardiographic 
systolic and diastolic function parameters between 
SAD rats treated with carvedilol and the control group 
treated with vehicle (Table 2).
Preliminary analysis of histological sections evi-
denced lower degree of interstitial and perivascular 
fibrosis in the left ventricle of SAD rats with chronic 
carvedilol treatment compared with the SAD control 
group receiving vehicle (Figure 2). Finally, the ex-
pression of molecular markers of fibrosis established 
that chronic treatment of SAD rats with carvedilol 
30 mg/kg reduces TGF-β expression both in the left 
table 1. Hemodynamic parameters of sinoaortic-denervated rats 
chronically treated with carvedilol or vehicle.
Data are expressed as mean±standard error of the mean. * p<0.05 vs. 
vehicle SAD rats. SAD: Sinoaortic denervation. SBP: Systolic blood pres-
sure. SD: Standard deviation. MAP: Mean arterial pressure.
Hemodynamic parameter Vehicle SAD 
rats
 (n=6)
Carvedilol 
SAD rats 
(n=6)
indirect blood pressure
(tail cuff)
sBp, mmHg
intraday sD, mmHg
interday sD, mmHg
Direct blood pressure in the 
carotid artery
map, mmHg
sD, mmHg
percent coefficient of variation
142±5
6.0±0.2
7.3±0.9
106±6
9.2±0.7
8.7±1.0
126±2 *
2.9±0.2 *
7.0±1.3
93±8
5.8±1.3 *
6.2±0.5*
Fig. 1. Beat–to-beat variability at different ranges of frequency 
in sinoaortic-denervated rats after 8-week treatment with ve-
hicle (light bars) or carvedilol 30 mg/kg (dark bars). * p<0.05 
vs. vehicle-treated group. VLF: Very low frequency. LF: Low 
frequency. HF: High frequency. LF/HF: Low frequency/high fre-
quency ratio
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cardiographic parameters with respect to the vehicle-
treated group.
Compared to spontaneously hypertensive SAD 
rats (SHR-SAD), sinoaortic denervation in normoten-
sive animals represents the ideal experimental model 
to evaluate only the importance of BPV regulation in 
the reduction of cardiovascular events and target or-
gan injury. (3) Bilateral resection of carotid nerves in-
creases BP liability without highly significant changes 
in average BP values. (11) However, previous studies 
have detected an increase in SBP by the tail-cuff ple-
thysmography method. (11) In addition to hemody-
namic changes, elevated BPV in SAD animals is as-
sociated with increased target organ injury, including 
late left ventricular hypertrophy, increased fibrosis 
and myocardial wall thickening, aortic hypertrophy 
Fig. 2. Representative images 
(20×) of left ventricular Sirius 
Red staining, showing inter-
stitial and perivascular fibrosis. 
table 2. Main echocardiographic parameters in sinoaortic-de-
nervated rats after 8-week treatment with vehicle or carvedilol 
30 mg/kg.
Echocardiographic parameter Vehicle SAD rats
 (n=6)
Carvedilol SAD rats 
(n=6)
end-diastolic diameter, mm
end-systolic diameter, mm
ejection fraction (%)
isovolumic relaxation time, 
mseg
7.57±0.33
5.37±0.37
64.4±2.8
34.7±2.0
7.30±0.20
5.35±0.15
60.6±1.3
34.5±2.5
Data are expressed as mean±SEM. Non-significant p for carvedilol SAD 
rats vs. vehicle SAD rats.
with collagen accumulation, impaired arterial disten-
sibility and increased mesangial matrix. (3)
Preclinical evidence in SAD animals and clinical 
studies in hypertensive patients have led to postu-
late that increased BPV independently contributes 
to target organ injury associated with hypertension. 
(3) It has even been suggested that the poor cardio-
protective effect of beta-blockers compared with other 
antihypertensive drugs would be partly due to their 
neutral effect on BPV as opposed to the reduction de-
tected with other agents, especially dihydropyridine 
calcium blockers. (3, 5) In this context, it is necessary 
to emphasize that the main evidence of the neutral 
or negative beta-blocker effect on BPV comes from 
studies evaluating atenolol. It is uncertain whether 
lack of attenuation of this cardiovascular risk factor 
with atenolol could be extended to vasodilating beta-
blockers as carvedilol. In previous studies in SAD rats, 
we have reported that acute carvedilol administration 
produces a greater reduction of short-term BPV than 
atenolol. (6) Taking into account these studies, we 
compared chronic carvedilol treatment or vehicle on 
BPV and target organ injury in SAD rats. The analy-
sis of direct and indirect BP measurements showed 
that a daily single dose of carvedilol 30 mg/kg can 
significantly reduce the standard deviation of BP re-
cordings, a well-known parameter of short-term vari-
ability. Moreover, as indirect interday BP variation did 
not differ between the carvedilol and vehicle groups, 
it can be inferred that the vasodilator beta-blocker did 
not have a significant effect on day-to-day BPV.
In addition, chronic oral carvedilol administra-
Instertitial fibrosis
Perivascular fibrosis
Vehicle
Vehicle
Carvedilol
Carvedilol
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tion during 8 weeks significantly reduced beat-to-beat 
BPV in all the frequency domains. The identification 
of BPV frequency components by spectral analysis 
may provide insight into mechanisms involved in BP 
regulation. (12) Thus, the quantification of variability 
in the LF, HF domains, and the estimation of the LF/
HF ratio allow to indirectly assess BP modulation by 
endothelial nitric oxide and vascular sympathetic ac-
tivity, respectively. (12) Compared with vehicle treat-
ment, chronic carvedilol administration reduced the 
LF/HF ratio showing its ability to inhibit sympathetic 
vascular activity.
The study showed mixed results on target organ 
injury. Carvedilol did not reduce left ventricular and 
thoracic aorta morphometric hypertrophy markers or 
echocardiographic parameters compared with the ve-
hicle group. However, the analysis of left ventricular 
histological samples and the level of TGF-β expression 
showed that chronic carvedilol therapy is able to re-
duce the degree of myocardial and vascular fibrosis in 
SAD rats. Lack of carvedilol efficacy on morphometric 
markers could be explained by late left ventricular hy-
pertrophy developing only after 10-16 weeks following 
SAD. (13)
CONCLUSIONS
In conclusion, chronic carvedilol administration is ef-
fective to reduce beat-to-beat and short-term BPV in 
an experimental model of BP liability. Although BPV 
attenuation in carvedilol-treated SAD animals did not 
have beneficial effects on ventricular hypertrophy 
markers and systolic and diastolic functional param-
eters, the vasodilating beta-blocker prevented, at least 
partially, myocardial fibrosis and TGF-β profibrotic 
factor expression.
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